Intensity Therapeutics (NASDAQ:INTS) Stock Price Up 2.1% – Time to Buy?

Intensity Therapeutics Inc. (NASDAQ:INTS)’s share price traded up 2.1% during trading on Thursday. The company traded as high as $3.51 and last traded at $3.2070. 6,838 shares changed hands during mid-day trading, a decline of 72% from the average daily volume of 24,141 shares. The stock had previously closed at $3.14.

Wall Street Analyst Weigh In

INTS has been the topic of a number of research analyst reports. HC Wainwright lifted their price target on shares of Intensity Therapeutics from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Tuesday, August 18th. Citigroup restated a “buy” rating on shares of Intensity Therapeutics in a research report on Tuesday, August 11th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Intensity Therapeutics in a report on Monday. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $7.00.

Intensity Therapeutics Trading Down 0.3%

The company has a 50 day simple moving average of $3.87 and a 200 day simple moving average of $4.32. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.00 and a current ratio of 5.00. The company has a market capitalization of $10.37 million, a PE ratio of -0.89 and a beta of 2.81.

Intensity Therapeutics (NASDAQ:INTS) last announced its earnings results on Tuesday, August 11th. The company reported ($1.11) EPS for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.24). Analysts anticipate that Intensity Therapeutics Inc. will post -2.64 earnings per share for the current year.

Intensity Therapeutics Company Profile

Intensity Therapeutics, Inc is a clinical-stage biotechnology company developing cancer immunotherapies designed to treat solid tumors. The company’s approach is based on its proprietary INTASYL technology, which is intended to enable therapeutic compounds to enter tumor cells directly, promote cancer-cell death and stimulate an immune response against tumor tissue.

Intensity Therapeutics’ lead investigational product, INT230-6, is an intratumoral therapy formulated to deliver anticancer agents directly into tumors.